RAM
TVTX icon

Readystate Asset Management’s Travere Therapeutics TVTX Stock Holding History

Readystate Asset Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-322,235
Closed -$5.61M – 746
2024
Q4 		$5.61M Sell
322,235
-10,704
-3% -$189K 0.17% 128
2024
Q3 		$4.66M Buy
+332,939
New +$3.47M 0.09% 296

Other funds holding TVTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Readystate Asset Management's TVTX Position: Q1 2025 in Review

Readystate Asset Management sold out of Travere Therapeutics (TVTX) in Q1 2025, closing a stake of 322,235 shares — an estimated $5.61M sold.

Readystate Asset Management first reported a position in TVTX in Q3 2024 and held it in 2 quarters. The position peaked at $5.61M in Q4 2024. 218 funds tracked by Wall St. Rank hold TVTX as of Q1 2025.

  • Readystate Asset Management reported no remaining Travere Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Readystate Asset Management sold 322,235 Travere Therapeutics shares in Q1 2025, an estimated $5.61M.
  • Readystate Asset Management first reported a position in Travere Therapeutics in Q3 2024 and held it in 2 quarters.
  • Readystate Asset Management's Travere Therapeutics position peaked at $5.61M in Q4 2024.
  • 218 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2025.

Based on Readystate Asset Management's 13F filing for Q1 2025, filed 6 May 2025.